Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients
Forty refractory schizophrenic patients (21 females and 19 males) participated in a fixed‐dose study with clozapine. After a 6‐week trial of haloperidol and a 1‐week washout time period, non‐responding patients were placed on clozapine and the dosage titrated up to 400 mg/day for the next 5 weeks. P...
Saved in:
| Published in | Human psychopharmacology Vol. 12; no. 5; pp. 489 - 495 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Chichester, UK
John Wiley & Sons, Ltd
01.09.1997
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Forty refractory schizophrenic patients (21 females and 19 males) participated in a fixed‐dose study with clozapine. After a 6‐week trial of haloperidol and a 1‐week washout time period, non‐responding patients were placed on clozapine and the dosage titrated up to 400 mg/day for the next 5 weeks. Plasma clozapine levels and its two metabolites desmethylclozapine (DCLOZ) and clozapine N‐oxide (CNO) were measured at weeks 2, 4 and 6. Blood samples were obtained 10–12 h post‐evening dose and prior to the morning dose. Clozapine and its metabolites were assayed by HPLC with UV detection. Patients were assessed for clinical response with the Brief Psychiatric Rating Scale (BPRS) at baseline and at weeks 2, 4 and 6. BPRS scores were also divided into positive (+) and negative (−) symptoms subscales. Plasma clozapine and DCLOZ levels were significantly lower in males. Plasma CNO levels were slightly lower in males but it was not statistically significant. Decreased total BPRS, (+) and (−) symptoms subscale scores occurred during the study for both gender groups. A greater magnitude of change for the (−) symptom subscale score was observed in the male group. Gender was not a significant factor in the incidence or severity of side‐effects. © 1997 John Wiley & Sons, Ltd. |
|---|---|
| AbstractList | Forty refractory schizophrenic patients (21 females and 19 males) participated in a fixed‐dose study with clozapine. After a 6‐week trial of haloperidol and a 1‐week washout time period, non‐responding patients were placed on clozapine and the dosage titrated up to 400 mg/day for the next 5 weeks. Plasma clozapine levels and its two metabolites desmethylclozapine (DCLOZ) and clozapine N‐oxide (CNO) were measured at weeks 2, 4 and 6. Blood samples were obtained 10–12 h post‐evening dose and prior to the morning dose. Clozapine and its metabolites were assayed by HPLC with UV detection. Patients were assessed for clinical response with the Brief Psychiatric Rating Scale (BPRS) at baseline and at weeks 2, 4 and 6. BPRS scores were also divided into positive (+) and negative (−) symptoms subscales. Plasma clozapine and DCLOZ levels were significantly lower in males. Plasma CNO levels were slightly lower in males but it was not statistically significant. Decreased total BPRS, (+) and (−) symptoms subscale scores occurred during the study for both gender groups. A greater magnitude of change for the (−) symptom subscale score was observed in the male group. Gender was not a significant factor in the incidence or severity of side‐effects. © 1997 John Wiley & Sons, Ltd. |
| Author | Wei, Fu-Chuan Lin, Shi-Kwang Liu, Hui-Ching Hu, Wei-Herng Lin, Shih-Ku Jann, Michael W. Chang, Wen-Ho |
| Author_xml | – sequence: 1 givenname: Michael W. surname: Jann fullname: Jann, Michael W. organization: Mercer University, Southern School of Pharmacy, Atlanta, GA, USA – sequence: 2 givenname: Hui-Ching surname: Liu fullname: Liu, Hui-Ching organization: Taipei City Psychiatric Centre, 309 Sung-Te Road, Taipei, Taiwan, 10510, Republic of China – sequence: 3 givenname: Fu-Chuan surname: Wei fullname: Wei, Fu-Chuan organization: Hung-Chi Psychiatric Hospital, Taipei, Taiwan, Republic of China – sequence: 4 givenname: Shi-Kwang surname: Lin fullname: Lin, Shi-Kwang organization: Taipei City Psychiatric Centre, 309 Sung-Te Road, Taipei, Taiwan, 10510, Republic of China – sequence: 5 givenname: Shih-Ku surname: Lin fullname: Lin, Shih-Ku organization: Taipei City Psychiatric Centre, 309 Sung-Te Road, Taipei, Taiwan, 10510, Republic of China – sequence: 6 givenname: Wei-Herng surname: Hu fullname: Hu, Wei-Herng organization: Taipei City Psychiatric Centre, 309 Sung-Te Road, Taipei, Taiwan, 10510, Republic of China – sequence: 7 givenname: Wen-Ho surname: Chang fullname: Chang, Wen-Ho organization: Taipei City Psychiatric Centre, 309 Sung-Te Road, Taipei, Taiwan, 10510, Republic of China |
| BookMark | eNqF0EtLxDAQwPEgCq6P75CjHro7SbdNs4qwVF0XxBV8IR6GtJ1itNuWpvj69HateFHwFJjJ_A7_LbZeViUxNhUwFABytHc1j-f7ArT2BCi1J7RWoEcC9oWcBIfjSE8m0_mxd3ZzqYU48ocwjBcH0ovW2ODnap0NIIoCL5RSbrIt554Auh3oAXuYUZlRwzOb59RQmZLjtuR1YdzS8LSoPkxtS-IFvVDhuCkzblvHl9SapCps23936aP9qOrHDrApr01rqWzdDtvITeFo9_vdZjenJ9fxmXe-mM3j6bmX-oESnlFSaEkUCJmFJJRRmQilTpIogrEJTK6zhCCUEeTdME1krqk7UXqs0iCExN9m972bNpVzDeVYN3ZpmncUgKuKiKuKuOqBqx7YV_xaSwywq4jYVcS-IvoIGC9QYtTZD739agt6_wX_7_7Jfk863et161p6-9FN84yh8lWAdxczlPEslrd3Pp76n1mLmPg |
| Cites_doi | 10.1016/0006-3223(95)00138-7 10.1016/0006-2952(93)90272-X 10.1046/j.1365-2125.1996.35418.x 10.1055/s-2007-979584 10.1111/j.1365-2125.1995.tb04471.x 10.1002/j.1552-4604.1994.tb02000.x 10.1176/ajp.149.5.587 10.2165/00023210-199504050-00006 10.1111/j.1365-2125.1994.tb04385.x 10.1001/archpsyc.1988.01800330013001 10.1176/ajp.151.1.123 10.1176/ajp.153.6.820 10.1046/j.1365-2125.1996.03482.x 10.2466/pr0.1962.10.3.799 10.1111/j.1365-2125.1994.tb04242.x 10.2165/00003088-199324020-00005 10.1016/0378-4347(92)80554-4 10.1097/00004714-199312000-00003 10.2165/00003495-199550020-00003 10.1097/00007691-199408000-00006 10.1176/ajp.147.11.1471 10.1097/00007691-199604000-00015 10.1007/BF00442557 10.1007/BF02245621 10.1016/0378-4347(93)80212-M |
| ContentType | Journal Article |
| Copyright | Copyright © 1997 John Wiley & Sons, Ltd. |
| Copyright_xml | – notice: Copyright © 1997 John Wiley & Sons, Ltd. |
| DBID | BSCLL AAYXX CITATION |
| DOI | 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8 |
| DatabaseName | Istex CrossRef |
| DatabaseTitle | CrossRef |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1099-1077 |
| EndPage | 495 |
| ExternalDocumentID | 10_1002__SICI_1099_1077_199709_10_12_5_489__AID_HUP911_3_0_CO_2_8 HUP911 ark_67375_WNG_2CGC2VW3_F |
| Genre | article |
| GrantInformation_xml | – fundername: Taipei City Government – fundername: National Science Council funderid: NSC 83‐0412‐B109‐001 |
| GroupedDBID | --- .3N .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3SF 3WU 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHHS AANLZ AAONW AASGY AAVGM AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABHUG ABIJN ABIVO ABPTK ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXME ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFVGU AFZJQ AGJLS AHBTC AHMBA AIACR AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRMAN DRSTM EAD EAP EBC EBD EBS EJD EMB EMK EMOBN EPL EPS ESTFP ESX F00 F01 F04 F5P FEDTE FUBAC G-S G.N GAKWD GNP GODZA H.X HF~ HHY HHZ HVGLF HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M6M MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWD RWI RX1 RYL SAMSI SUPJJ SV3 TEORI TUS UB1 V2E W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR XG1 XV2 ZZTAW ~IA ~WT AITYG HGLYW OIG AAYXX CITATION |
| ID | FETCH-LOGICAL-c3571-a72192ee512d6e17a7d1629bb8804a5af9dbe06280f9bbcb2f9e7217947c560b3 |
| IEDL.DBID | DR2 |
| ISSN | 0885-6222 |
| IngestDate | Fri Aug 23 01:38:14 EDT 2024 Sat Aug 24 00:54:27 EDT 2024 Wed Jan 17 05:00:25 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3571-a72192ee512d6e17a7d1629bb8804a5af9dbe06280f9bbcb2f9e7217947c560b3 |
| Notes | National Science Council - No. NSC 83-0412-B109-001 Taipei City Government ark:/67375/WNG-2CGC2VW3-F istex:B821989EC31AEA5EE8B287A294B9D857E982C467 ArticleID:HUP911 |
| PageCount | 7 |
| ParticipantIDs | crossref_primary_10_1002__SICI_1099_1077_199709_10_12_5_489__AID_HUP911_3_0_CO_2_8 wiley_primary_10_1002_SICI_1099_1077_199709_10_12_5_489_AID_HUP911_3_0_CO_2_8_HUP911 istex_primary_ark_67375_WNG_2CGC2VW3_F |
| PublicationCentury | 1900 |
| PublicationDate | 1997-09 September/October 1997 1997-09-00 |
| PublicationDateYYYYMMDD | 1997-09-01 |
| PublicationDate_xml | – month: 09 year: 1997 text: 1997-09 |
| PublicationDecade | 1990 |
| PublicationPlace | Chichester, UK |
| PublicationPlace_xml | – name: Chichester, UK |
| PublicationTitle | Human psychopharmacology |
| PublicationTitleAlternate | Hum. Psychopharmacol. Clin. Exp |
| PublicationYear | 1997 |
| Publisher | John Wiley & Sons, Ltd |
| Publisher_xml | – name: John Wiley & Sons, Ltd |
| References | Jann, M. W., Lam, Y. W. F. and Chang, W. H. (1994). Rapid formation of clozapine in guinea pigs and man following clozapine N-oxide administration. Archives International Pharmacodyanmie Therapie, 328, 243-250. Weigmann, H. and Hiemke, C. (1992). Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high performance liquid chromatography. Journal of Chromatography, 583, 209-216. Brosen, K., Skjelbo, E., Rasmussen, B. B., Poulsen, H. E. and Loft, S. (1993). Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochemical Pharmacology, 45, 1211-1214. Centorrino, F., Baldessarini R. J., Kando, J. A. Frankenburg, F. R., Volpicelli, S. A., Puopolo, P. R. and Flood, J. G. (1994). Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate. American Journal of Psychiatry, 151, 123-125. Lin, S. K., Chang, W. H., Chung, M. C., Lam, Y. W. F. and Jann, M. W. (1994). Disposition of clozapine and desmethylclozapine in schizophrenic patients. Journal of Clinical Pharmacology, 34, 318-324. Haring, C., Meise, U., Humpel, C., Saria, A., Fleischhacker, W. W. and Hinterhuber, H. (1989). Dose-related plasma levels of clozapine: influence of smoking, behavior, sex and age. Psychopharmacology, 99, S38-S40. Jerling, M., Lindstrom, L., Bondesson, U. and Bertilsson, L. (1994). Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Therapeutic Drug Monitoring, 16, 368-374. Fischer, V., Vogels, B., Naurer, G. and Tynes, R. E. (1992). The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P4502D6. Journal of Pharmacology and Experimental Therapeutics, 260, 1355-1360. Haring, C., Fleischhacker, W., Schett, P., Humpel, C., Barnas, C. and Saria, A. (1990). Influence of patient-related variables on clozapine plasma levels. American Journal of Psychiatry, 147, 1471-1475. Centorrino, F., Baldessarini R. J., Frankenburg F. R., Kando, J., Volpicelli, S. A. and Flood, J. G. (1996). Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. American Journal of Psychiatry, 153, 820-822. Szymanski, S., Lieberman, J., Pollack, S., Kane, J. M., Safferman, A., Munne, R., Umbricht, D., Woerner, M., Masiar, S. and Kronig, M. (1996). Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biological Psychiatry, 39, 249-254. Chung, M. C., Lin, S. K., Chang, W. H. and Jann, M. W. (1993). Determination of clozapine and desmethyl clozapine in human plasma by high performance liquid chromatography. Journal of Chromatography, 613, 168-173. Cognex package insert, Parke-Davis, August 1995. Wagsta, A. J. and Bryson, H. M. (1995). Clozapine. CNS Drugs, 4, 370-400. Bertilsson, L., Carrillo, J. A., Dahl, M. L., Lierena, A., Alm, C., Bondesson, U., Lindstrom, L., de la Rubia, I. R., Ramos, S. and Benitez, J. (1994). Clozapine disposition covaries with CYP 1A2 activity determined by a caffeine test. British Journal of Clinical Pharmacology, 38, 471-473. Pirmohamed, M., Williams D., Madden S., Templeton, E. and Park, B. K. (1995). Metabolism and bioactivation of clozapine by human live in vitro. Journal of Pharmacology and Experimental Therapeutics, 272, 984-990. Tiihonen, J., Vartianinen, H. and Hakola, P. (1995). Carbamazepine induced changes in plasma levels of neuroleptics. Pharmacopsychiatry, 28, 26-28. Aranz, M. J., Dawson, E., Shaikh, S., Sharn, P., Sharma, T., Aitchison, K., Crocq, M. A., Gill, M., Kerwin, R. and Collier, D. A. (1995). Cytochrome P4502D6 does not determine response to clozapine. British Journal of Clinical Pharmacology, 39, 417-420. Park, B. N., Kitteringham, N. R., Pirmohamed, M. and Tucker, G. T. (1996). Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implication. British Journal of Clinical Pharmacology, 41, 477-491. Lui, H. C., Chang, W. H., Wei, F. C., Lin, S. K., Lin, S. K. and Jann, M. W. (1996). Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Therapeutic Drug Monitoring, 18, 200-207. Hasegawa, M., Gutierrez-Esteinou, R., Way, L. and Meltzer, H. Y. (1993). Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. Journal of Clinical Psychopharmacology, 13, 383-390. Dahl, M. L., Llerena, A., Bondesson, U., Lindstrom, L. and Bertilsson, L. (1994). Disposition of clozapine in man: lack of association with debrisoquine and S-mephentoin hydroxylation polymorphism. British Journal of Clinical Pharmacology, 37, 71-74. Kane, J., Honigfeld, G., Singer, J., Meltzer, H. Y. and The Clozaril Study Group (1988). Clozapine for the treatment resistant schizophrenic. Archives of General Psychiatry, 45, 789-796. Fabrazzo, M., Esposito, G., Fusco, R. and Maj, M. (1996). Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Psychopharmacology, 124, 197-200. Harris, R. Z., Benet, L. and Schwartz, J. B. (1995). Gender effects in pharmacokinetics and pharmacodynamics. Drugs, 50, 75-89. Potkin, S. G., Bera, R., Gulasekaram, B., Costa, J., Hayes, S., Jin, Y., Richmond, G., Carreon, D., Sitanggan, K. and Gerber, B. (1994). Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. Journal of Clinical Psychiatry, 55, 133-136. Yonkers, K. A., Kando J. A., Cole, J. O. and Blumenthal, S. (1992). Gender differences in pharma-cokinetics and pharmacodynamics of psychotropic medication. American Journal of Psychiatry, 149, 587-595. Overall, J. E. and Gorham, D. R. (1962). The brief psychiatric rating scale. Psychology Report, 10, 799-812. Jann, M. W., Grimsley, S. R., Gray, E. C. and Chang, W. H. (1993). Pharmacokinetics and pharmacodynamics of clozapine. Clinical Pharmacokinetics, 24, 161-176. Carrillo, J. A. and Benitez, J. (1996). CYP 1A2 activity, gender and smoking, as variables in fluencing the toxicity of caffeine. British Journal of Clinical Pharmacology, 41, 605-608. 1993; 24 1993; 45 1995; 50 1996; 18 1996; 39 1992; 260 1990; 147 1995; 39 1992; 583 1994; 151 1992; 149 1995 1962; 10 1996; 124 1995; 4 1995; 272 1993; 13 1993; 613 1989; 99 1995; 28 1994; 34 1994; 55 1996; 41 1988; 45 1994; 38 1994; 16 1994; 37 1996; 153 1994; 328 Haring (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB12) 1990; 147 Aranz (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB1) 1995; 39 Fischer (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB11) 1992; 260 Carrillo (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB4) 1996; 41 Lin (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB20) 1994; 34 Wagsta (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB28) 1995; 4 Pirmohamed (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB24) 1995; 272 Fabrazzo (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB10) 1996; 124 Park (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB23) 1996; 41 Overall (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB22) 1962; 10 (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB8) 1995 Hasegawa (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB15) 1993; 13 Yonkers (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB30) 1992; 149 Dahl (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB9) 1994; 37 Haring (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB13) 1989; 99 Kane (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB19) 1988; 45 Jann (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB16) 1993; 24 Brosen (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB3) 1993; 45 Centorrino (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB5) 1994; 151 Jerling (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB18) 1994; 16 Potkin (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB25) 1994; 55 Bertilsson (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB2) 1994; 38 Harris (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB14) 1995; 50 Lui (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB21) 1996; 18 Centorrino (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB6) 1996; 153 Szymanski (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB26) 1996; 39 Chung (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB7) 1993; 613 Tiihonen (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB27) 1995; 28 Weigmann (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB29) 1992; 583 Jann (10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB17) 1994; 328 |
| References_xml | – volume: 10 start-page: 799 year: 1962 end-page: 812 article-title: The brief psychiatric rating scale publication-title: Psychology Report – volume: 41 start-page: 477 year: 1996 end-page: 491 article-title: Relevance of induction of human drug‐metabolizing enzymes: pharmacological and toxicological implication publication-title: British Journal of Clinical Pharmacology – volume: 39 start-page: 249 year: 1996 end-page: 254 article-title: Gender differences in neuroleptic nonresponsive clozapine‐treated schizophrenics publication-title: Biological Psychiatry – volume: 153 start-page: 820 year: 1996 end-page: 822 article-title: Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors publication-title: American Journal of Psychiatry – volume: 16 start-page: 368 year: 1994 end-page: 374 article-title: Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service publication-title: Therapeutic Drug Monitoring – volume: 124 start-page: 197 year: 1996 end-page: 200 article-title: Effect of treatment duration on plasma levels of clozapine and N‐desmethylclozapine in men and women publication-title: Psychopharmacology – volume: 50 start-page: 75 year: 1995 end-page: 89 article-title: Gender effects in pharmacokinetics and pharmacodynamics publication-title: Drugs – volume: 45 start-page: 1211 year: 1993 end-page: 1214 article-title: Fluvoxamine is a potent inhibitor of cytochrome P450 1A2 publication-title: Biochemical Pharmacology – volume: 149 start-page: 587 year: 1992 end-page: 595 article-title: Gender differences in pharma‐cokinetics and pharmacodynamics of psychotropic medication publication-title: American Journal of Psychiatry – volume: 4 start-page: 370 year: 1995 end-page: 400 article-title: Clozapine publication-title: CNS Drugs – volume: 28 start-page: 26 year: 1995 end-page: 28 article-title: Carbamazepine induced changes in plasma levels of neuroleptics publication-title: Pharmacopsychiatry – volume: 99 start-page: S38 year: 1989 end-page: S40 article-title: Dose‐related plasma levels of clozapine: influence of smoking, behavior, sex and age publication-title: Psychopharmacology – volume: 37 start-page: 71 year: 1994 end-page: 74 article-title: Disposition of clozapine in man: lack of association with debrisoquine and S‐mephentoin hydroxylation polymorphism publication-title: British Journal of Clinical Pharmacology – volume: 55 start-page: 133 year: 1994 end-page: 136 article-title: Plasma clozapine concentrations predict clinical response in treatment‐resistant schizophrenia publication-title: Journal of Clinical Psychiatry – volume: 272 start-page: 984 year: 1995 end-page: 990 article-title: Metabolism and bioactivation of clozapine by human live in vitro publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 328 start-page: 243 year: 1994 end-page: 250 article-title: Rapid formation of clozapine in guinea pigs and man following clozapine ‐oxide administration publication-title: Archives International Pharmacodyanmie Therapie – volume: 38 start-page: 471 year: 1994 end-page: 473 article-title: Clozapine disposition covaries with CYP 1A2 activity determined by a caffeine test publication-title: British Journal of Clinical Pharmacology – volume: 260 start-page: 1355 year: 1992 end-page: 1360 article-title: The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P4502D6 publication-title: Journal of Pharmacology and Experimental Therapeutics – volume: 147 start-page: 1471 year: 1990 end-page: 1475 article-title: Influence of patient‐related variables on clozapine plasma levels publication-title: American Journal of Psychiatry – volume: 13 start-page: 383 year: 1993 end-page: 390 article-title: Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking publication-title: Journal of Clinical Psychopharmacology – volume: 24 start-page: 161 year: 1993 end-page: 176 article-title: Pharmacokinetics and pharmacodynamics of clozapine publication-title: Clinical Pharmacokinetics – volume: 151 start-page: 123 year: 1994 end-page: 125 article-title: Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate publication-title: American Journal of Psychiatry – year: 1995 – volume: 45 start-page: 789 year: 1988 end-page: 796 article-title: Clozapine for the treatment resistant schizophrenic publication-title: Archives of General Psychiatry – volume: 18 start-page: 200 year: 1996 end-page: 207 article-title: Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients publication-title: Therapeutic Drug Monitoring – volume: 34 start-page: 318 year: 1994 end-page: 324 article-title: Disposition of clozapine and desmethylclozapine in schizophrenic patients publication-title: Journal of Clinical Pharmacology – volume: 39 start-page: 417 year: 1995 end-page: 420 article-title: Cytochrome P4502D6 does not determine response to clozapine publication-title: British Journal of Clinical Pharmacology – volume: 41 start-page: 605 year: 1996 end-page: 608 article-title: CYP 1A2 activity, gender and smoking, as variables in fluencing the toxicity of caffeine publication-title: British Journal of Clinical Pharmacology – volume: 613 start-page: 168 year: 1993 end-page: 173 article-title: Determination of clozapine and desmethyl clozapine in human plasma by high performance liquid chromatography publication-title: Journal of Chromatography – volume: 583 start-page: 209 year: 1992 end-page: 216 article-title: Determination of clozapine and its major metabolites in human serum using automated solid‐phase extraction and subsequent isocratic high performance liquid chromatography publication-title: Journal of Chromatography – volume: 39 start-page: 249 year: 1996 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB26 publication-title: Biological Psychiatry doi: 10.1016/0006-3223(95)00138-7 contributor: fullname: Szymanski – volume: 45 start-page: 1211 year: 1993 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB3 publication-title: Biochemical Pharmacology doi: 10.1016/0006-2952(93)90272-X contributor: fullname: Brosen – volume: 41 start-page: 605 year: 1996 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB4 publication-title: British Journal of Clinical Pharmacology doi: 10.1046/j.1365-2125.1996.35418.x contributor: fullname: Carrillo – volume: 28 start-page: 26 year: 1995 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB27 publication-title: Pharmacopsychiatry doi: 10.1055/s-2007-979584 contributor: fullname: Tiihonen – volume: 39 start-page: 417 year: 1995 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB1 publication-title: British Journal of Clinical Pharmacology doi: 10.1111/j.1365-2125.1995.tb04471.x contributor: fullname: Aranz – volume: 34 start-page: 318 year: 1994 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB20 publication-title: Journal of Clinical Pharmacology doi: 10.1002/j.1552-4604.1994.tb02000.x contributor: fullname: Lin – volume: 149 start-page: 587 year: 1992 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB30 publication-title: American Journal of Psychiatry doi: 10.1176/ajp.149.5.587 contributor: fullname: Yonkers – volume: 55 start-page: 133 year: 1994 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB25 publication-title: Journal of Clinical Psychiatry contributor: fullname: Potkin – volume: 4 start-page: 370 year: 1995 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB28 publication-title: CNS Drugs doi: 10.2165/00023210-199504050-00006 contributor: fullname: Wagsta – volume: 272 start-page: 984 year: 1995 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB24 publication-title: Journal of Pharmacology and Experimental Therapeutics contributor: fullname: Pirmohamed – volume: 328 start-page: 243 year: 1994 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB17 publication-title: Archives International Pharmacodyanmie Therapie contributor: fullname: Jann – volume: 38 start-page: 471 year: 1994 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB2 publication-title: British Journal of Clinical Pharmacology doi: 10.1111/j.1365-2125.1994.tb04385.x contributor: fullname: Bertilsson – volume: 45 start-page: 789 year: 1988 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB19 publication-title: Archives of General Psychiatry doi: 10.1001/archpsyc.1988.01800330013001 contributor: fullname: Kane – volume: 151 start-page: 123 year: 1994 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB5 publication-title: American Journal of Psychiatry doi: 10.1176/ajp.151.1.123 contributor: fullname: Centorrino – volume: 153 start-page: 820 year: 1996 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB6 publication-title: American Journal of Psychiatry doi: 10.1176/ajp.153.6.820 contributor: fullname: Centorrino – volume: 260 start-page: 1355 year: 1992 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB11 publication-title: Journal of Pharmacology and Experimental Therapeutics contributor: fullname: Fischer – volume: 41 start-page: 477 year: 1996 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB23 publication-title: British Journal of Clinical Pharmacology doi: 10.1046/j.1365-2125.1996.03482.x contributor: fullname: Park – volume: 10 start-page: 799 year: 1962 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB22 publication-title: Psychology Report doi: 10.2466/pr0.1962.10.3.799 contributor: fullname: Overall – volume: 37 start-page: 71 year: 1994 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB9 publication-title: British Journal of Clinical Pharmacology doi: 10.1111/j.1365-2125.1994.tb04242.x contributor: fullname: Dahl – volume-title: Cognex package insert year: 1995 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB8 – volume: 24 start-page: 161 year: 1993 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB16 publication-title: Clinical Pharmacokinetics doi: 10.2165/00003088-199324020-00005 contributor: fullname: Jann – volume: 583 start-page: 209 year: 1992 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB29 publication-title: Journal of Chromatography doi: 10.1016/0378-4347(92)80554-4 contributor: fullname: Weigmann – volume: 13 start-page: 383 year: 1993 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB15 publication-title: Journal of Clinical Psychopharmacology doi: 10.1097/00004714-199312000-00003 contributor: fullname: Hasegawa – volume: 50 start-page: 75 year: 1995 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB14 publication-title: Drugs doi: 10.2165/00003495-199550020-00003 contributor: fullname: Harris – volume: 16 start-page: 368 year: 1994 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB18 publication-title: Therapeutic Drug Monitoring doi: 10.1097/00007691-199408000-00006 contributor: fullname: Jerling – volume: 147 start-page: 1471 year: 1990 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB12 publication-title: American Journal of Psychiatry doi: 10.1176/ajp.147.11.1471 contributor: fullname: Haring – volume: 18 start-page: 200 year: 1996 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB21 publication-title: Therapeutic Drug Monitoring doi: 10.1097/00007691-199604000-00015 contributor: fullname: Lui – volume: 99 start-page: s38 year: 1989 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB13 publication-title: Psychopharmacology doi: 10.1007/BF00442557 contributor: fullname: Haring – volume: 124 start-page: 197 year: 1996 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB10 publication-title: Psychopharmacology doi: 10.1007/BF02245621 contributor: fullname: Fabrazzo – volume: 613 start-page: 168 year: 1993 ident: 10.1002/(SICI)1099-1077(199709/10)12:5<489::AID-HUP911>3.0.CO;2-8-BIB7 publication-title: Journal of Chromatography doi: 10.1016/0378-4347(93)80212-M contributor: fullname: Chung |
| SSID | ssj0009909 |
| Score | 1.6045212 |
| Snippet | Forty refractory schizophrenic patients (21 females and 19 males) participated in a fixed‐dose study with clozapine. After a 6‐week trial of haloperidol and a... |
| SourceID | crossref wiley istex |
| SourceType | Aggregation Database Publisher |
| StartPage | 489 |
| SubjectTerms | clozapine clozapine metabolites gender schizophrenia |
| Title | Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients |
| URI | https://api.istex.fr/ark:/67375/WNG-2CGC2VW3-F/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2F%28SICI%291099-1077%28199709%2F10%2912%3A5%3C489%3A%3AAID-HUP911%3E3.0.CO%3B2-8 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1db9MwFLWmISFeYHyJwkB-oNUmLV1sx_koCKmEdS0SWzXabRIPlu240rQtq5ZMYnvjr_BLuY7ThgESTwipD1GS5qT3-l4f19fHCL2OdWhiCcPUgEjqBQlRniJKeoYzCfw0ylg1FfNpLxxOg4_H_HgFfVushXH6EMs_3GxkVPnaBrhUxXYjGgoE7PMoHcGA2U7uQDqxk4-xrZuoJDSJb69Q8DNvszSIEziCT3_0wRtOxxDibbbDun433W-z95AUIItbOT5Lqw4aASrI1YnjodwLoSu9i_r1G2xvWPTNJfaGQ4YX3CS0x98CYq_XoL1zWG8A6VYPeMc68-ttZlx1bYMH6PvCKK6i5bR7VaquvvlFL_K_Wm0N3a-JM-67lv4QrZj8EeqMnfL29RaeNAvJii3cweNGk_v6MfritszDi_1gIDvikxzPYexwLrE-u7iRc_ht-MzWUBVY5hk-KQt8bkoIErtMu7q9-KlCUeNakrZ4gqaDnUk69Op9JTzNeEQ8CaPehBoDXCcLDYlklJGQJkpBLgskl7MkU8auLfVncFIrOksMfAUyV6SBICr2FK3mF7l5hjD3Q60NkOpA6iAKtIwVI3rG4iwgvg55Cx0sfC3mTj5EOKFoKoR1hK0ASIR1g3BOqC5TwQUYXwgwvHCGF0z4It0XVMQt1KlazfKJ8vLU1udFXBzt7Qqa7qb08IiJQQtNqrbwG_Tfkf8IXJ95_m8e-wLdc9rAtoBvHa2Wl1fmJTC-Ur2qgvIHCx0yJQ |
| link.rule.ids | 315,786,790,1382,27955,27956,46327,46751 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1bb9MwFLbGJgEv3BHl6gdabdLSJXacS0FIJVvXwtZVo2WTeLBsx5WmbVm1ZBLbI3-FP8pxnDYMkHhCSH2okjZfco7P8ef4-DNCryMV6EjAMNX3BHH82JOO9KRwNKMC-GmY0nIqZncY9Cf-h0N2uIS-zdfCWH2IxQs3ExllvjYBbl5Ib9SqocDAPg2SAYyYzewO5BMz-xiZwolSQ9NzzRkCjmZNmvhRDN_g0x1sOv3JCGK8Sbdo220ne036HrLCDbQCSYOZ4N7cryWoIFvHlokyJ4DO9CbqVrewsWrg1xbgqxYa7nDNIx32FiA7nRrunQV7A1DX-sAV486v17lx2bn17qLvc7PYmpbj9kUh2-rqF8XI_2u3e-hOxZ1x1zb2-2hJZw9Qa2TFty_X8bheS5av4xYe1bLclw_RF7trHp5vCQMJEh9leAbDh1OB1cnZlZjBw-ETU0aVY5Gl-KjI8akuIE7MSu3y5_lPRYoKV6q0-SM06W2Nk75TbS3hKMpCzxEw8I2J1kB30kB7oQhTLyCxlJDOfMHENE6lNstL3SkcVJJMYw1_geQVKuCIkj5Gy9lZpp8gzNxAKQ282hfKD30lIkk9NaVR6nuuClgD7c-dzWdWQYRbrWjCuXGEKQKIuXEDt04oTxPOOBifczA8t4bnlLs82eOERw3UKpvN4ori_NiU6IWMHwy3OUm2E_L5gPJeA43LxvAb9N-R_whcHXn6by77Ct3qj3d3-M5g-PEZum2lgk0933O0XJxf6BdAAAv5sozQH27bNkU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwxV1ba9swFBZdC2Uvu49lVz0soYU6tSXLl2wMMqdpsksaumQt7EFIsgylrRvqFNa-7a_sl-7IcuJ1G-xpDPxgfPvsc3SOzrGOPiH0MlKBjgSkqb4niOPHnnSkJ4WjGRUQn4YpLYdiPo6CwdR_d8gOV9C3xVwYyw-x_OFmLKP018bAZ2m2XZOGQgD2aZgMIWE2gzvgTszgY2TqJkoKTc81ZwjomTVp4kcx7MHWHfacwXQMJt6kO7TttpO9Jn0LTuEGWvMDSkz-1tuvGajAWcc2EGVOAH3pOupWr7C9YeA3l-AbFhrecNMjHfYaIDudGu6NBXsFUNe6wDWjza_XQ-Oyb-vfRt8XUrElLcfti7lsq6tfCCP_q9juoFtV5Iy7tqnfRSs6v4daY0u9fbmFJ_VMsmILt_C4JuW-vI--2DXz8GJBGHCP-CjHM0geTgVWJ2dXYgbfhk9MEVWBRZ7io3mBT_UcrMTM0y4vL34qUVS44qQtHqBpf2eSDJxqYQlHURZ6joC0NyZaQ7CTBtoLRZh6AYmlBGfmCyayOJXaTC51MzioJMliDbeA6woVRIiSPkSr-VmuHyHM3EApDVG1L5Qf-kpEknoqo1Hqe64KWAPtL3TNZ5Y_hFumaMK5UYQpAYi5UQO3SihPE844CJ9zEDy3gueUuzzZ44RHDdQqW83yieL82BTohYwfjHY5SXYT8vmA8n4DTcq28Bv035H_CFwdefxvHvsCrY97ff5hOHr_BN20PMGmmO8pWp2fX-hnEP3N5fPSPn8AZnY09A |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Gender+differences+in+plasma+clozapine+levels+and+its+metabolites+in+schizophrenic+patients&rft.jtitle=Human+psychopharmacology&rft.au=Jann%2C+Michael+W.&rft.au=Liu%2C+Hui%E2%80%90Ching&rft.au=Wei%2C+Fu%E2%80%90Chuan&rft.au=Lin%2C+Shi%E2%80%90Kwang&rft.date=1997-09-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=0885-6222&rft.eissn=1099-1077&rft.volume=12&rft.issue=5&rft.spage=489&rft.epage=495&rft_id=info:doi/10.1002%2F%28SICI%291099-1077%28199709%2F10%2912%3A5%3C489%3A%3AAID-HUP911%3E3.0.CO%3B2-8&rft.externalDBID=10.1002%252F%2528SICI%25291099-1077%2528199709%252F10%252912%253A5%253C489%253A%253AAID-HUP911%253E3.0.CO%253B2-8&rft.externalDocID=HUP911 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0885-6222&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0885-6222&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0885-6222&client=summon |